论文部分内容阅读
日前,CSL有限公司在2012年美国心脏病学会年会上公布了载脂蛋白A-I新制剂CSL112的若干项临床或体外研究结果。其中一项在36名健康受试者中进行的Ⅰ期临床研究表明:该药可显著促进胆固醇的逆向转运,从而使停留在动脉中的胆固醇转运到肝脏中进行清除。心脏病发作后所产生的胆固醇如能得以快速清除,可能对降低心脏病发作的风险有积极作用。此外,CSL112在该项试验中还表现出良好的安全性:治疗中无严重不良反应的报告,最常见不良反
Recently, CSL Ltd. announced a number of clinical or in vitro studies of CSL112, a new apolipoprotein A-I preparation, at the 2012 American College of Cardiology Annual Meeting. One Phase I clinical trial conducted in 36 healthy subjects showed that the drug significantly promoted the reverse transport of cholesterol, allowing the cholesterol remaining in the artery to be transported to the liver for clearance. Cholesterol, which is produced after a heart attack, if cleared quickly, may have a positive effect on reducing the risk of a heart attack. In addition, CSL112 also demonstrated good safety in this trial: reports of no serious adverse effects during treatment, the most common adverse reactions